Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as FKC289 injection
FKC289 · 1 trial · 1 indication
Number of subjects experiencing DLT
Number of subjects experiencing AEs and SAEs
Number of subjects with positive detection of RCL
| Arm | Type | Description |
|---|---|---|
| FKC289 injection | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FKC289 injection | DRUG | Anti-BCMA/CD19 chimeric antigen receptor autologous T cells |
Inclusion Criteria: 1. Voluntarily signed the informed consent form (ICF); 2. Aged between 18-70 years old (inclusive); 3. Histologically confirmed diagnosis of primary membranous nephropathy by renal biopsy obtained within the past 2 years.; 4. Relapsed or refractory disease; 5. Anti-PLA2R antibod...
FKC289 is an investigational small molecule being developed for the treatment of Primary Membranous Nephropathy, a kidney disease. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
FKC289 is being developed by Kairos Pharma, Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol KAPA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
FKC289 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The ongoing trial is a Phase I/II open-label, single-arm, multicenter study designed to evaluate its safety and efficacy.
FKC289 is being studied in a Phase I/II clinical trial with the identifier NCT07765537. This open-label, single-arm, multicenter study is enrolling 55 participants with relapsed or refractory Primary Membranous Nephropathy in China. The trial is not yet recruiting participants.
Yes, FKC289 is also known as FKC289 injection. Both names refer to the same investigational drug being developed by Kairos Pharma, Ltd. for the treatment of Primary Membranous Nephropathy.